Inertia is a barrier as is the traditional split between the clinical and the data-driven spheres of drug development. While smaller firms have an edge in bridging the gap, big pharma will eventually get there, said panelists at the INVEST conference session.

Source: AI offers promise but faces barriers in drug development

Leave a Reply

Your email address will not be published.